TABLE 1.
N = 50 | |
---|---|
Gender | |
Male | 28 (56%) |
Female | 22 (44%) |
Race | |
African-American | 7 (14%) |
Caucasian | 43 (86%) |
Diagnosis | |
Brain tumor | 31 (62%) |
Non-brain tumor | 19 (38%) |
Age at diagnosis (yrs) | |
Mean | 7.39 |
Median (Range) | 6.90 (0.40 – 16.20) |
Age at screening (yrs) | |
Mean | 13.2 |
Median (Range) | 14.2 (6.1 – 17.99) |
Brain Surgery | |
Yes | 31 (62%) |
No | 19 (38%) |
Primary tumor in brain | |
None/biopsy of brain | 5 (10%) |
Partial/total resection | 27 (54%) |
No primary tumor in brain | |
None/biopsy of brain | 18 (36%) |
Radiation to head/neck | |
Yes | 35 (70%) |
No | 15 (30%) |
Cisplatin | |
Yes | 19 (38%) |
No | 31 (62%) |
Carboplatin | |
Yes | 14 (28%) |
No | 36 (72%) |
Vancomycin | |
Yes | 9 (19.6%) |
No | 37 (80.4%) |
Missing | 4 |
Aminoglycosides | |
Yes | 3 (6.5%) |
No | 43 (93.5%) |
Missing | 4 |
Hearing loss | |
Yes | 17 (40.5%) |
No | 25 (59.5%) |
Missing | 8 |
End of treatment to screening (yrs) | |
Mean | 4.77 |
Median (Range) | 4.25 (0.17 – 13.88) |